HeartFlow’s first full quarter as a public company turned into a blowout. After the closing bell on August 13, 2026, the AI cardiology-imaging company reported Q2 2026 revenue of $64.1 million, up 48% year over year, and raised its full-year outlook for the second time in three months. Shares of Nasdaq-listed HTFL soared roughly 36% on August 14 to a fresh all-time high near $42, more than doubling the company’s $19 IPO price from August 2025.
The report is the first clear signal since the IPO that HeartFlow’s two commercial products — its flagship FFRCT blood-flow analysis and the newer Plaque diagnostic — are compounding faster than the sell side had modeled. Management now expects 40%–42% revenue growth for 2026, up from 29%–32% guided just one quarter earlier.
The headline numbers
The top-line acceleration is real: growth moved from 41% in Q1 to 48% in Q2, with U.S. revenue up 51%. Non-GAAP gross margin expanded to 83.3%, an unusually high level for a devices/analytics business and one that management attributed to AI-driven automation of the case-processing workflow. The GAAP loss per share of ($0.07) landed well ahead of the ($0.14)–($0.19) analyst range published by the aggregators.
| Metric | Q1 2026 | Q2 2026 | YoY (Q2) |
|---|---|---|---|
| Total revenue | $52.6M | $64.1M | +48% |
| U.S. revenue growth | n/d | — | +51% |
| Non-GAAP gross margin | 80.5% | 83.3% | +~770 bps |
| GAAP EPS | $(0.16) | $(0.07) | — |
| Plaque product revenue | n/d | $7.8M | — |
The guide raise nobody saw coming
Guidance is where the report separated itself. HeartFlow now expects FY2026 revenue of $246 million to $250 million, versus the $228M–$232M range set at Q1 and the $218M–$222M range set at the IPO. Non-GAAP gross margin is now projected at 82% for the full year (up from 81%). Within that, revenue from the Plaque diagnostic — HeartFlow’s newer, higher-priced product line — was lifted to $29M–$31M, roughly a $4 million bump.
Two things stand out about the shape of the raise. First, the midpoint has moved roughly 14% higher in just three months — a meaningful signal that management is seeing accelerating case volumes rather than one-off timing. Second, the implied H2 run-rate (about $130M against H1 of $116.7M) still leaves modest cushion; the company did not fully bake in Q2’s growth rate.
What HeartFlow actually sells
HeartFlow’s flagship product, FFRCT, is an AI-powered non-invasive test that estimates fractional flow reserve — the pressure ratio across a coronary artery narrowing — using a standard coronary CT scan. The technology received an original De Novo clearance from the FDA in 2014 (DEN130045) after a series of pivotal trials (DISCOVER-FLOW, DeFACTO, and NXT) documented higher diagnostic accuracy versus CT angiography alone. A 2024 peer-reviewed review in PMC summarizes the clinical evidence base underpinning payer adoption in the U.S.
The newer product, launched in September 2025 after FDA 510(k) clearance, is the next-generation Plaque analysis platform, which quantifies coronary plaque burden and composition. It is the growth engine investors are now paying for: at the raised midpoint, Plaque revenue would triple in 2026 from a smaller 2025 base.
Why the stock ripped
Three ingredients drove the ~36% move: a clean revenue beat, a large guide raise, and a gross-margin print that quietly resets the profitability story. On the last point, management reiterated it expects to reach cash-flow profitability by mid-2028 — a datable, testable target that gives long-only funds a specific milestone to underwrite against.
Context matters. FFRCT-style AI diagnostics have long been a “when, not if” story in cardiology; the sell side has typically discounted uptake by a year or two because provider adoption cycles are slow. HeartFlow’s 48% Q2 growth — with U.S. up 51% and gross margins above 83% — suggests the adoption curve has finally steepened. That is what a $42 print on a $19 IPO is telling you.
Risks worth naming
- Concentration risk. HeartFlow is a two-product company, and Plaque is very early. A trial setback, a payer reimbursement change, or slower-than-expected physician onboarding could unwind the multiple.
- Reimbursement. Category III CPT codes and evolving Medicare payment for AI-enabled diagnostics remain a moving target. Any adverse rate change would flow directly through to unit economics.
- Insider supply. Post-IPO lockup expirations and secondary offerings are common in the 6-to-12-month window after a debut. Investors should track HeartFlow’s Form 4 and prospectus supplement filings on EDGAR.
- Valuation. At $42 and roughly 200 million shares outstanding, HTFL now trades at more than 30x forward revenue — priced for continued execution.
What to watch next
The Q2 10-Q will be the next primary document to consult; it will detail cash burn, operating expenses, share-count movement, and any updates to the reimbursement footnotes. Beyond the print itself, watch for Plaque case-volume disclosures, any new payer contracts (particularly commercial), and the pace of international expansion, which management has previously flagged as an incremental leg.
Sources
- HeartFlow — Q1 2026 financial results press release (May 14, 2026)
- HeartFlow — Investor Relations news releases (index)
- HeartFlow — Form 10-Q, quarter ended March 31, 2026 (SEC EDGAR)
- FDA — De Novo summary DEN130045 (FFRCT V. 1.4)
- HeartFlow — FDA 510(k) clearance for next-generation Plaque analysis (Sep 22, 2025)
- IPOScoop — HeartFlow prices IPO at $19, above range (Aug 2025)
- Seeking Alpha — HeartFlow projects $246M–$250M 2026 revenue as Plaque outlook rises to $29M–$31M
- Benzinga — HeartFlow shares soar following strong Q2 results and upgraded guidance
- The Motley Fool — Why HeartFlow stock soared today (Aug 14, 2026)
- PMC / NCBI — CT-derived Fractional Flow Reserve clinical review
Disclosure: This article is for informational purposes only and is not investment advice.